When treated with EGFR-tyrosine kinase inhibitor (TKI), some EGFR-mutated NSCLC patients may undergo rare pathological transformations to SCLC (4), which is an important mechanism for resistance to EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.